HISUN(SH:600267)2018-04-26 16:00Financial Performance - Net profit attributable to shareholders was CNY 10.79 million, representing a 57.95% increase year-on-year[6]. - Operating revenue for the period was CNY 2.82 billion, up 3.06% from the same period last year[6]. - Basic earnings per share rose to CNY 0.011, a 57.14% increase year-on-year[6]. - Net profit attributable to the parent company increased by 57.95% to RMB 10,790,753.78, driven by improved gross margins and government subsidies[14]. - The company reported a significant increase in net profit despite a loss in net profit after deducting non-recurring gains and losses, which amounted to CNY -6.90 million[6]. - Net profit for Q1 2018 reached CNY 130,511,771.18, a significant increase of 62.5% compared to CNY 80,321,592.01 in Q1 2017[27]. - The company reported a total profit of CNY 44,954,108.26 for Q1 2018, compared to a total loss of CNY 10,404,173.94 in the same quarter last year, marking a substantial improvement[30]. Cash Flow - Net cash flow from operating activities increased by 237.93% to CNY 285.46 million compared to the previous year[6]. - Operating cash flow for Q1 2018 was CNY 285,464,905.20, compared to CNY 84,475,183.38 in Q1 2017, indicating an increase of approximately 237%[34]. - Cash inflow from operating activities totaled CNY 2,668,540,330.90, compared to CNY 2,410,418,671.83 in the previous year, representing an increase of approximately 10.7%[33]. - Total cash outflow from operating activities was $664,048,200.40, compared to $607,157,687.58 in the previous period, showing an increase of approximately 9%[37]. - The company experienced a 562.98% decrease in cash flow from financing activities, totaling RMB -331,137,823.40, primarily due to loan repayments[14]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 21.75 billion, a 0.51% increase compared to the end of the previous year[6]. - Total current assets decreased from CNY 6,944,131,941.27 to CNY 6,883,716,410.73, a decline of approximately 0.88%[18]. - Total non-current assets increased from CNY 14,692,286,737.64 to CNY 14,863,327,277.82, reflecting a growth of about 1.16%[19]. - Total liabilities decreased from CNY 13,761,135,195.76 to CNY 13,738,750,315.44, a reduction of about 0.16%[20]. - Total equity increased from CNY 7,875,283,483.15 to CNY 8,008,293,373.11, reflecting a growth of approximately 1.68%[20]. Shareholder Information - The total number of shareholders at the end of the reporting period was 28,438[10]. - The largest shareholder, Zhejiang Haizheng Group Co., Ltd., held 33.22% of the shares[10]. Expenses and Income - Sales expenses increased by 58.15% to RMB 517,357,672.31, mainly due to higher marketing costs for the formulation business[13]. - Other income rose by 265.04% to RMB 24,941,281.15, primarily from increased government subsidies received by Hai Zheng Pfizer[13]. - The company reported a total of CNY 24,941,281.15 in other income for Q1 2018, up from CNY 6,832,476.57 in Q1 2017, indicating a substantial increase of 264.56%[27]. - Financial expenses for Q1 2018 were CNY 87,130,305.74, compared to CNY 71,559,096.79 in the previous year, representing a rise of 21.76%[27]. Tax and Regulatory Matters - The company reported a significant increase in tax payable by 91.90% to RMB 125,478,277.62, due to increased VAT and income tax obligations[13]. - The company plans to submit materials for a non-public offering of A-shares, pending approval from the China Securities Regulatory Commission[14].